Tesofensine vs Vesilute
Side-by-side comparison of key properties, dosing, and research.
Fat Loss & Metabolic
TesofensineAnti-Aging & Longevity
Vesilute- Summary
- Tesofensine is a triple monoamine reuptake inhibitor (TMRI) that blocks reuptake of serotonin, dopamine, and norepinephrine. Originally developed for Alzheimer's and Parkinson's disease, it was repurposed as a potent weight loss agent after clinical trials demonstrated substantial fat loss via appetite suppression and increased energy expenditure.
- Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
- Half-Life
- 8-10 days (exceptionally long; accumulates over weeks)
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Oral
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.25-0.5 mg per day
- 10 mg per day
- Frequency
- Once daily
- Daily for 10–30 days
- Key Benefits
- Potent appetite suppression via triple monoamine reuptake inhibition
- Significant weight loss (8-12% body weight in phase II trials at 0.5 mg)
- Increases basal metabolic rate and energy expenditure
- Reduces fat mass preferentially over lean mass
- Potential cognitive benefit via dopaminergic and noradrenergic enhancement
- Longer half-life than sibutramine allows once-daily dosing
- Supports retinal photoreceptor cell function and survival
- May slow progression of age-related macular degeneration
- Reduces retinal cell apoptosis from oxidative stress and aging
- Anti-aging effects on retinal pigment epithelium
- Potential support in diabetic retinopathy management
- Preserves visual acuity with aging
- Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
- Side Effects
- Elevated heart rate and blood pressure (sympathomimetic)
- Dry mouth
- Insomnia and sleep disturbances
- Nausea
- +4 more
- Generally well tolerated
- Mild injection site reactions
- No significant ocular adverse events reported at standard doses
- Stacks With
- —
- —